Ybiologics
Korea’s Leading Antibody Therapeutics Development Company
- Business Model
- B2B
- Website
- ybiologics.com
- Total Funding
- $25.3M
- Last Round
- $25.3M Convertible NoteAug 2025
- Rounds
- 1
About
Y-Biologics develops novel antibody-based therapeutics through its proprietary pipeline and strategic partnerships, using antibody-discovery and engineering technologies. Its Multi-AbKine platform combines bispecific antibodies with cytokines to pursue cancers that are unresponsive or resistant to existing immunotherapies. The company also develops modalities including antibody humanization, pH-dependent antibodies, and antibody-drug conjugates for varied applications.
Summary
Ybiologics is a Biotech company. It has raised $25.3M in total across 1 round, most recently a $25.3M Convertible Note round in Aug 2025. Investors include AJU IB Investment, DSC Investment and Partners Investment.
Funding History
Aug 2025
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/ybiologics"><img src="https://indexed.vc/api/badge/company/ybiologics" alt="Ybiologics on Indexed.vc" width="260" height="76" /></a>